RoslinCT continues its growth plans by expanding its operations at Edinburgh Technopole
Edinburgh, UK, 08 June 2022 – RoslinCT – a cell and gene therapy/ATMP CDMO, developing life-changing cell and gene therapies in Edinburgh’s BioQuarter– signs lease for 1,453 sqm additional space at Charles Darwin House at the Edinburgh Technopole.
The additional space will include fully fitted Process Development labs and offices to further support RoslinCT’s growth plans. The Process Development lab space (511m2) gives the company expanded capabilities not only for pluripotent cell processing and genome editing but also on viral cell modification and greater scale up/scale out of cell therapy manufacturing processes and will allow the further expansion of the business. The fit-out of the new space has been completed and has already welcomed the RoslinCT Process Development team.
The brand-new office space further supports the company’s rapid growth and provides ample space for 20+ team members to continue offering bespoke cell and gene therapy services to clients worldwide.
Last year, the company introduced its brand-new state-of-the-art cell and gene therapy manufacturing facility and more than doubled its headcount in 2021.
“Continuing our rapid growth, I am very pleased with the expansion of our operations to Edinburgh Technopole.”, says Peter Coleman, CEO of RoslinCT. “This new location provides us with the opportunity to further expand our Process Development capacity and capabilities and meet the growing needs of our sector.”
Located in the heart of the Midlothian Science Zone innovation cluster to the south of Edinburgh, Technopole offers a high-quality mix of flexible offices, high specification laboratories and product development space, with good car parking and support services plus, excellent transport links to Edinburgh city centre and Edinburgh Airport.
Simon Hoad, Executive Director of We Are Pioneer Group, said: “We are delighted to welcome RoslinCT to Edinburgh Technopole. We continue to invest in infrastructure and support and, we look forward to working with the team on their future business growth”.
RoslinCT is a leading UK Cell Therapy Contract Development and Manufacturing Organisation (CDMO) focused on providing services for companies developing cell-based therapeutic products. Originally founded in 2006 as a spin-out from the Roslin Institute, we built on the broad range of scientific expertise available in the field of cell biology. Based at the Edinburgh BioQuarter, we operate fully licensed GMP manufacturing facilities and have a proven track record in the delivery of cell-based products. www.roslinct.com.
About GHO Capital
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high-growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market-leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit www.ghocapital.com.